Options of Therapeutics and Novel Delivery Systems of Drugs for the Treatment of Melanoma.

Melanoma is one of the most severe cancerous diseases. The cells employ multiple signaling pathways, such as ERK, HGF/c-MET, WNT, and COX-2 to cause the cell proliferation, survival, and metastasis. Treatment of melanoma, including surgery, chemotherapy, immunotherapy, radiation, and targeted therapy, is based on 4 major or 11 substages of the disease. Fourteen drugs, including dacarbazine, interferon α-2b, interleukin-12, ipilimumab, peginterferon α-2b, vemurafenib, trametinib, talimogene laherparepvec, cobimetinib, pembrolizumab, dabrafenib, binimetinib, encorafenib, and nivolumab, have been approved by the FDA for the treatment of melanoma. All of them are in conventional dosage forms of injection solutions, suspensions, oral tablets, or capsules. Major drawbacks of the treatment are side effects of the drugs and patients' incompliance to them. These are consequences of high doses and long-term treatments for the diseases. Currently more than 350 NCI-registered clinical trials are being carried out to treat advanced and/or metastatic melanoma using novel treatment methods, such as immune cell therapy, cancer vaccines, and new therapeutic targets. In addition, novel delivery systems using biomaterials of the approved drugs have been developed attempting to increase the drug delivery, targeting, stability, bioavailability, thus potentially reducing the toxicity and increasing the treatment effectiveness. Nanoparticles and liposomes have been emerging as advanced delivery systems which can improve drug stability and systemic circulation time. In this review, the most recent findings in the options for treatment and development of novel drug delivery systems for the treatment of melanoma are comprehensively discussed.

• Publication year

  2022

• Venue

  Molecular Pharmaceutics

• Publication date

  2022-10-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1021/acs.molpharmaceut.2c00775PMID 36305753
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Managing Metastatic Melanoma in 2022: A Clinical Review.

  2022cited by this paper
• Sonodynamic Therapy Using Dacarbazine-Loaded AuSiO2 Nanoparticles for Melanoma Treatment: An In-Vitro Study on the B16F10 Murine Melanoma Cell Line.

  2022cited by this paper
• Synthesis, Characterization, and In Vivo Cytokinome Profile of IL-12-Loaded PLGA Nanospheres

  2022cited by this paper
• Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy.

  2022cited by this paper
• Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy

  2022cited by this paper
• Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials

  2022cited by this paper
• Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma

  2021cited by this paper
• Multi-functional carboxymethyl chitin-based nanoparticles for modulation of tumor-associated macrophage polarity.

  2021cited by this paper
• A PD1 targeted nano-delivery system based on epigenetic alterations of T cell responses in the treatment of gastric cancer

  2021cited by this paper
• Efficacy and safety of combined brain radiotherapy and immunotherapy in melanoma patients with brain metastases: A systematic review and meta-analysis.

  2021cited by this paper
• The Role of HGF/MET Signaling in Metastatic Uveal Melanoma

  2021cited by this paper
• Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma

  2021cited by this paper
• Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma

  2021cited by this paper
• IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy.

  2021cited by this paper
• Radiation therapy for uveal melanoma: a review of treatment methods available in 2021

  2021cited by this paper
• RAC1 Activation as a Potential Therapeutic Option in Metastatic Cutaneous Melanoma

  2021cited by this paper
• The Role of Melanoma Cell-Derived Exosomes (MTEX) and Photodynamic Therapy (PDT) within a Tumor Microenvironment

  2021cited by this paper
• Co-delivery of IL-12 cytokine gene and cisplatin prodrug by a polymetformin-conjugated nanosystem for lung cancer chemo-gene treatment through chemotherapy sensitization and tumor microenvironment modulation.

  2021cited by this paper
• Melanoma: An Update on Systemic Therapies.

  2021cited by this paper
• Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review

  2021cited by this paper
• Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

  2021cited by this paper
• Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review

  2021cited by this paper
• Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)

  2021cited by this paper
• STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation

  2021cited by this paper
• Dual Encapsulated Dacarbazine and Zinc Phthalocyanine Polymeric Nanoparticle for Photodynamic Therapy of Melanoma

  2021cited by this paper
• Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

  2021cited by this paper
• A Theranostic Cellulose Nanocrystal-Based Drug Delivery System with Enhanced Retention in Pulmonary Metastasis of Melanoma.

  2021cited by this paper
• Co-delivery of Dacarbazine and All-Trans Retinoic Acid (ATRA) Using Lipid Nanoformulations for Synergistic Antitumor Efficacy Against Malignant Melanoma

  2020cited by this paper
• Immunostimulatory Effects of Radiotherapy for Local and Systemic Control of Melanoma: A Review

  2020cited by this paper
• Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

  2020cited by this paper
• Melanoma Peptide MHC Specific TCR Expressing T-Cell Membrane Camouflaged PLGA Nanoparticles for Treatment of Melanoma Skin Cancer

  2020cited by this paper
• Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma

  2020cited by this paper
• Co‐Delivery of Paclitaxel and Interleukin‐12 Regulating Tumor Microenvironment for Cancer Immunochemotherapy

  2020cited by this paper
• Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations

  2020cited by this paper
• Immunotherapy for Melanoma.

  2020cited by this paper
• SMARCA family of genes

  2020cited by this paper
• WNT Signaling in Melanoma

  2020cited by this paper
• Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis

  2020cited by this paper
• Targeted melanoma radiotherapy using ultrasmall 177Lu-labeled α-melanocyte stimulating hormone-functionalized core-shell silica nanoparticles.

  2020cited by this paper
• Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex

  2020cited by this paper
• The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment

  2020cited by this paper
• COX-2 as a potential biomarker and therapeutic target in melanoma

  2020cited by this paper
• Cancer Cell Coating Nanoparticles for Optimal Tumor-Specific Cytokine Delivery.

  2020cited by this paper
• Comparative Analysis of Au and Au@SiO2 Nanoparticle–Protein Interactions for Evaluation as Platforms in Theranostic Applications

  2020cited by this paper
• MET-dependent solid tumours — molecular diagnosis and targeted therapy

  2020cited by this paper
• Melanoma pathology reporting and staging

  2019cited by this paper
• Wnt Signaling and Biological Therapy in Rheumatoid Arthritis and Spondyloarthritis

  2019cited by this paper
• Cholesterol‐conjugated PEGylated PAMAM as an efficient nanocarrier for plasmid encoding interleukin‐12 immunogene delivery toward colon cancer cells

  2019cited by this paper
• Photothermal Therapy Promotes Tumor Infiltration and Antitumor Activity of CAR T Cells

  2019cited by this paper
• Targeting the ERK Signaling Pathway in Melanoma

  2019cited by this paper
• Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)

  2019cited by this paper
• EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma

  2019cited by this paper
• Co-Delivery of Eugenol and Dacarbazine by Hyaluronic Acid-Coated Liposomes for Targeted Inhibition of Survivin in Treatment of Resistant Metastatic Melanoma

  2019cited by this paper
• Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review

  2019cited by this paper
• Current state of melanoma diagnosis and treatment

  2019cited by this paper
• Targeting ERK1/2 protein-serine/threonine kinases in human cancers.

  2019cited by this paper
• Immunotherapy of Melanoma: Facts and Hopes

  2019cited by this paper
• Synthesis and characterization of a novel biocompatible pseudo-hexagonal NaCa-layered double metal hydroxides for smart pH-responsive drug release of dacarbazine and enhanced anticancer activity in malignant melanoma.

  2019cited by this paper
• Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma

  2019cited by this paper
• Boosting Interleukin-12 Antitumor Activity and Synergism with Immunotherapy by Targeted Delivery with isoDGR-Tagged Nanogold.

  2019cited by this paper
• Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+ T cells

  2018cited by this paper
• Extracellular Matrix Influencing HGF/c-MET Signaling Pathway: Impact on Cancer Progression

  2018cited by this paper
• HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers

  2018cited by this paper
• Structural snapshots of RAF kinase interactions.

  2018cited by this paper
• Peptide-modified vemurafenib-loaded liposomes for targeted inhibition of melanoma via the skin.

  2018cited by this paper
• Hepatocyte Growth Factor Activator: A Proteinase Linking Tissue Injury with Repair

  2018cited by this paper
• Talimogene laherparepvec: First in class oncolytic virotherapy

  2018cited by this paper
• Metformin: Focus on Melanoma

  2018cited by this paper
• Microneedle-Assisted Topical Delivery of Photodynamically Active Mesoporous Formulation for Combination Therapy of Deep-Seated Melanoma.

  2018cited by this paper
• HGF/c-MET Signaling in Melanocytes and Melanoma

  2018cited by this paper
• The Evolution of Radiation Therapy in Treating Cancer.

  2018cited by this paper
• MEK inhibitors for the treatment of NRAS mutant melanoma

  2018cited by this paper
• High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer

  2018cited by this paper
• SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.

  2018cited by this paper
• A novel vehicle for local protein delivery to the inner ear: injectable and biodegradable thermosensitive hydrogel loaded with PLGA nanoparticles

  2018cited by this paper
• Targeting Rac and Cdc42 GTPases in Cancer.

  2018cited by this paper
• Phase I/II Study of Hepatic Arterial Infusion of Nab-paclitaxel in Patients With Metastatic Melanoma to the Liver

  2018cited by this paper
• Role of Epigenetics in Uveal Melanoma

  2017cited by this paper
• Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine

  2017cited by this paper
• KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma

  2017cited by this paper
• Current Development Status of MEK Inhibitors

  2017cited by this paper
• Wnt/ b -Catenin Signaling, Disease, and Emerging Therapeutic Modalities

  2017cited by this paper
• A compendium of ERK targets

  2017cited by this paper
• Calcium Phosphate Particles as Pulmonary Delivery System for Interferon-α in Mice

  2017cited by this paper
• Targeting the Ras palmitoylation/depalmitoylation cycle in cancer.

  2017cited by this paper
• T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity

  2017cited by this paper
• Dual-specificity phosphatase 5 controls the localized inhibition, propagation, and transforming potential of ERK signaling

  2017cited by this paper
• PEGylated liposomes for topical vaginal therapy improve delivery of interferon alpha

  2017cited by this paper
• RAS Proteins and Their Regulators in Human Disease.

  2017cited by this paper
• Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

  2017cited by this paper
• Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

  2017cited by this paper
• The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy

  2017cited by this paper
• COX-2 expression positively correlates with PD-L1 expression in human melanoma cells

  2017cited by this paper
• The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology.

  2017cited by this paper
• DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers

  2017cited by this paper
• Hepatocyte growth factor/MET in cancer progression and biomarker discovery

  2017cited by this paper
• TREX1 dictates the immune fate of irradiated cancer cells

  2017cited by this paper
• Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study

  2017cited by this paper
• Varying Effects of EGF, HGF and TGFβ on Formation of Invadopodia and Invasiveness of Melanoma Cell Lines of Different Origin

  2016cited by this paper
• Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.

  2016cited by this paper

• PEPAD: A Promising Therapeutic Approach for the Treatment of Murine Melanoma (B16F10-Nex2)

  2025cites this paper
• Advancements in Skin Cancer Prevention and Treatment: Harnessing Technology, Natural Therapies, and Emerging Diagnostic Approaches.

  2025cites this paper
• The Role of Prostaglandin Pathway and EP Receptors in Skin Cancer Development

  2025cites this paper
• Emerging role of deubiquitinases in modulating cancer chemoresistance.

  2025cites this paper
• Genistein and Curcumin Inhibit Proliferation and Invasiveness in BRAFV600E Mutant and Wild-Type Melanoma Cells: Insights into Their Anticancer Effects

  2025cites this paper
• Microneedle pretreatment and cationic nanoparticles for transdermal delivery of doxorubicin against melanoma

  2024cites this paper
• Cyclooxygenase-2 (COX-2) Expression in Equine Melanocytic Tumors

  2024cites this paper
• Cryptotanshinone inhibits PFK-mediated aerobic glycolysis by activating AMPK pathway leading to blockade of cutaneous melanoma

  2024cites this paper
• Self-supplying Cu2+ and H2O2 synergistically enhancing disulfiram-mediated melanoma chemotherapy

  2024cites this paper
• Synthesis of 3-formyl-eudistomin U with anti-proliferation, anti-migration and apoptosis-promoting activities on melanoma cells

  2023cites this paper
• Programmed cell death‐1 blockade therapy in melanoma: Resistance mechanisms and combination strategies

  2023cites this paper
• Survival Mechanisms of Metastatic Melanoma Cells: The Link between Glucocorticoids and the Nrf2-Dependent Antioxidant Defense System

  2023cites this paper
• Preclinical Activity of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine in Melanoma

  2023cites this paper
• BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current Knowledge

  2023cites this paper
• T Cells Expressing CAR Equipped With Extracellular Domain of BTLA Are Effective Against HVEM-over-expressing Melanoma Cell Lines

  2023cites this paper
• Photosensitizers-Loaded Nanocarriers for Enhancement of Photodynamic Therapy in Melanoma Treatment

  2023cites this paper
• The effect of sulindac on redox homeostasis and apoptosis-related proteins in melanotic and amelanotic cells

  2023cites this paper
• Identification of Active Compounds against Melanoma Growth by Virtual Screening for Non-Classical Human DHFR Inhibitors

  2022cites this paper
• LINC01296 promotes proliferation of cutaneous malignant melanoma by regulating miR-324-3p/MAPK1 axis

  2022cites this paper